Takeda's ENTYVIO Shows Promise in Pediatric Ulcerative Colitis with 47% Remission Rate in Phase 3 KEPLER Trial
核心洞察
Takeda (搜索)'s Phase 3 KEPLER study demonstrated that vedolizumab (ENTYVIO) achieved clinical remission in 47.3% of pediatric patients with moderately to severely active ulcerative colitis (搜索) at 54 weeks.
The study enrolled 120 children and adolescents aged 2-17 who had inadequate response to conventional treatments or TNF antagonists (搜索), representing a difficult-to-treat population with limited therapeutic options.
Vedolizumab's safety profile in pediatric patients was generally consistent with its established profile in adults, with no new safety signals identified.
Takeda (搜索) announced positive results from its pivotal Phase 3 KEPLER trial, demonstrating that vedolizumab (ENTYVIO) achieved clinical remission in nearly half of pediatric patients with moderately to severely active ulcerative colitis (搜索). The study, presented at the 21st Congress of the European Crohn's and Colitis Organisation (ECCO), represents a significant advancement for a patient population with limited treatment options.
Study Design and Patient Population
The KEPLER trial enrolled 120 children and adolescents aged 2 to 17 years with moderately to severely active ulcerative colitis (搜索) who had inadequate response to conventional treatments, including steroids (搜索) and immunomodulators (搜索), and/or tumor necrosis factor (搜索) (TNF) antagonists. The study design included a 14-week open-label induction period where all participants received intravenous vedolizumab, followed by a 40-week randomized, double-blind maintenance period.
Of the initial 120 patients, 93 who achieved clinical response at Week 14 were randomized to receive either low-dose or high-dose maintenance therapy with vedolizumab every 8 weeks. Dosing was weight-based, with participants weighing ≥30 kg receiving either 300 mg (high dose) or 150 mg (low dose), while those weighing 10-15 kg received 150 mg or 100 mg respectively.
Primary Efficacy Results
The study met its primary endpoint, with 47.3% of randomized patients achieving clinical remission at Week 54. Secondary endpoints also showed promising results, with more than one-third (34.7%) of patients achieving clinical remission at 14 weeks, and greater than 1 in 4 (29%) participants attaining sustained clinical remission at both Weeks 14 and 54.
"In the KEPLER study, we observed clinically meaningful improvements with vedolizumab in an especially difficult-to-treat patient population—children and adolescents who had failed on the current standard of care, including conventional therapies and/or tumor necrosis factor (搜索) (TNF) antagonists," said Dr. Ramalingam Arumugam, study investigator and pediatric gastroenterologist at MNGI Digestive Health (搜索) in Minnesota.
Safety Profile
The safety profile of vedolizumab in pediatric patients was generally consistent with its established profile in adults, with no new safety signals identified. The most frequently occurring treatment-emergent adverse events (≥10%) reported in the KEPLER study were upper respiratory infection (30%), ulcerative colitis (搜索) disease worsening (17.5%), and pyrexia (12.5%).
Clinical Significance and Regulatory Plans
The results address a significant unmet medical need in pediatric gastroenterology. "For too long, families and clinicians caring for children and adolescents with ulcerative colitis (搜索) have had limited therapeutic options," said Dr. Awny Farajallah, chief medical officer of Takeda (搜索). "The Phase 3 KEPLER results are encouraging and suggest that ENTYVIO, a therapy with a well-established role in the treatment of ulcerative colitis, may offer a meaningful benefit for patients as young as two years old."
Based on these results, Takeda (搜索) plans to submit marketing applications in the United States, the European Union, and other markets for intravenous ENTYVIO for the treatment of moderately to severely active ulcerative colitis (搜索) in children and adolescents ages 2-17.
About Vedolizumab
Vedolizumab is currently the only gut-selective biologic therapy available for ulcerative colitis (搜索) and Crohn's disease (搜索). It specifically binds to the alpha4beta7 integrin (搜索) and blocks its interaction with MAdCAM-1 (搜索), which is mainly expressed on gut endothelial cells. The drug is already approved for intravenous and subcutaneous administration in adults with moderately to severely active ulcerative colitis and Crohn's disease who have had inadequate response to conventional therapy or TNF antagonists (搜索).
Vedolizumab IV has been granted marketing authorization in more than 80 countries, including the United States and European Union, while the subcutaneous formulation has been approved in more than 50 countries. Globally, vedolizumab IV and SC have accumulated more than one million patient years of exposure to date.